An observational study in Chronic Myeloid Leukemia (CML), sponsored by Sohag University. Not yet recruiting. Per ClinicalTrials.gov, last updated 2026-11-20.
Sponsored by Sohag University · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Chronic myeloid leukemia is a myelo-proliferative neoplasm characterized by abnormal proliferation of myeloid cells. There is an accumulation of mature granulocytes in the blood and bone marrow.
The aim of the study is to study expression of CD38 and CD56 in patients with Chronic myeloid leukemia.
895 studies on the registry are indexed under Leukemia, Myelogenous, Chronic, BCR-ABL Positive; 105 are open to participants now.
This study's planned enrollment of 200 is above the median of 135 across 148 observational studies indexed under Leukemia, Myelogenous, Chronic, BCR-ABL Positive.
Browse Leukemia, Myelogenous, Chronic, BCR-ABL Positive studies →Sohag University is the lead sponsor of 1,236 studies on the registry; 639 are open to participants now.
Counted across the registry records on this site, refreshed daily.
patients in sohag city
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Diagnostic Test: cd 38 and cd 56
prescence of high percentage of cd38 and cd 56
an increased change in cd 38 and cd 56 in chronic leukemic patients
Time frame: 6 months
No study locations are listed for this record.
Plan to share: Undecided
No publications or documents are linked to this record.
Start is estimated for Dec 2026; primary completion for Jun 2027, 5 months later.
Of 45 non-industry observational studies under Leukemia, Myelogenous, Chronic, BCR-ABL Positive, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 46 and three quarters within 142. This study's planned 5 months is below that.
Counting every sponsor, half of 67 studies reached it within 53 months; a quarter within 39 and three quarters within 103.
Start moved once since we started tracking on Sep 25, 2026: Sep 2026 → Dec 2026, on Nov 20, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive →